These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 38030811)
1. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR. Bapat J; Yamamoto TM; Woodruff ER; Qamar L; Mikeska RG; Aird KM; Watson ZL; Brubaker LW; Bitler BG Cancer Gene Ther; 2024 Feb; 31(2):300-310. PubMed ID: 38030811 [TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
3. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643 [TBL] [Abstract][Full Text] [Related]
6. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751 [TBL] [Abstract][Full Text] [Related]
7. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer. Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925 [TBL] [Abstract][Full Text] [Related]
9. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma. Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089 [TBL] [Abstract][Full Text] [Related]
10. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer. Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157 [TBL] [Abstract][Full Text] [Related]
11. PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703. Wang F; Li Y; Han Y; Zhang Y; Wang H; Wang L; Wang C; Guo M; Li P Med Oncol; 2024 Jul; 41(8):207. PubMed ID: 39043895 [TBL] [Abstract][Full Text] [Related]
16. Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium. Wang KH; Chu SC; Chu TY Oncotarget; 2017 Sep; 8(37):61133-61145. PubMed ID: 28977852 [TBL] [Abstract][Full Text] [Related]
17. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model. Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899 [TBL] [Abstract][Full Text] [Related]
18. Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. Konishi I; Abiko K; Hayashi T; Yamanoi K; Murakami R; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M; J Gynecol Oncol; 2022 Sep; 33(5):e83. PubMed ID: 36032027 [TBL] [Abstract][Full Text] [Related]
19. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma. Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162 [TBL] [Abstract][Full Text] [Related]
20. The oncogenic ADAMTS1-VCAN-EGFR cyclic axis drives anoikis resistance and invasion in renal cell carcinoma. Wen YC; Lin YW; Ho KH; Yang YC; Lai FR; Chu CY; Chen JQ; Lee WJ; Chien MH Cell Mol Biol Lett; 2024 Sep; 29(1):126. PubMed ID: 39333870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]